MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
2.135
-0.095
-4.26%
Opening 15:02 09/09 EDT
OPEN
2.210
PREV CLOSE
2.230
HIGH
2.220
LOW
2.130
VOLUME
1.27M
TURNOVER
--
52 WEEK HIGH
2.680
52 WEEK LOW
1.050
MARKET CAP
949.98M
P/E (TTM)
-13.9542
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LXRX last week (0831-0904)?
Weekly Report · 2d ago
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
Barchart · 09/01 15:05
Lexicon announces results from post hoc analysis of SOLOIST-WHF trial
TipRanks · 08/31 12:55
Weekly Report: what happened at LXRX last week (0824-0828)?
Weekly Report · 08/31 09:34
Lexicon Earns Third $10 Mln Milestone Payment From Novo For LX9851
NASDAQ · 08/25 02:09
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)
TipRanks · 08/24 14:50
Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk
Dow Jones · 08/24 13:12
Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851
TipRanks · 08/24 12:45
More
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.